Today’s session had a very split personality — tech ripped higher, but the broader market is still not out of the woods.

The Nasdaq jumped over 2%, led by massive strength in AI and chip names like AVGO (+10%), GOOGL (+5%), MU (+7%), and TSLA (+7%). But even with that surge, the Nasdaq is still trading under its 50-day moving average, which keeps this bounce in “recovery mode,” not full risk-on yet.

Be sure to check out out our recent list of our Top 10 Stocks For November 2025.

Featuring stocks such as SOUN, PLTR, and more.

1 Year Chart:

Click here to see the chart

Buy Level:

Looking to buy in the $88 range.

Stop Loss:

Ideal stop loss is around $80.

Price Target:

I’d look to start selling around the $100 range.

Market Cap: $11.51B

Company Info:

Globus Medical Inc. (NYSE: GMED) is a medical technology company specializing in advanced musculoskeletal solutions, designing innovative implants, surgical tools, and robotic-assisted systems used in spine surgery and orthopedic care. The company develops next-generation devices that support minimally invasive procedures, improve patient outcomes, and enhance surgical precision. GMED’s mission is to transform spine and orthopedic treatment through cutting-edge engineering, robotics, and data-driven surgical technologies — establishing itself as a leader in the future of digital, efficient, and high-accuracy musculoskeletal medicine.

Why it’s a buy:

The stock is a buy in 2025 because Globus Medical (GMED) is one of the strongest players in the rapidly growing spine and orthopedic robotics market, a sector benefiting from long-term demand drivers like an aging population, rising rates of spinal conditions, and a global shift toward minimally invasive surgery. Unlike traditional device makers, Globus has built a fully integrated ecosystem of implants, navigation tools, and its ExcelsiusGPS robotic platform — giving it a competitive edge as hospitals increasingly adopt robotic-assisted surgical technologies.

Following its merger with NuVasive, GMED now commands one of the largest and most diversified spine portfolios in the industry, with significant cross-selling opportunities, cost synergies, and expanding international reach. While the broader medical device sector has seen volatility, Globus continues to post strong procedure growth and rising adoption of its robotics systems. As surgical robotics becomes standard of care and hospitals invest heavily in efficiency and precision, GMED is positioned as a high-conviction compounder with durable demand, expanding margins, and a long runway of innovation.

Revenue:

1 Year Chart:

Click here to see the chart

Buy Level:

Looking to buy in the $125 range.

Stop Loss:

Ideal stop loss is around $115.

Price Target:

I’d look to start selling around the $140 range.

Market Cap: $18.92B

Company Info:

Illumina Inc. (NASDAQ: ILMN) is a global leader in genomics and DNA sequencing technologies, providing the tools that power research, diagnostics, and precision medicine worldwide. The company develops high-throughput sequencing systems, consumables, and software that enable scientists and clinicians to analyze genetic information at scale — supporting breakthroughs in cancer detection, rare disease research, and population genomics. Illumina’s mission is to unlock the power of the genome by delivering state-of-the-art sequencing platforms that drive innovation across biotechnology, healthcare, and life-science research.

Why it’s a buy:

The stock is a buy in 2025 because Illumina remains a foundational leader in genomics at a time when demand for genetic testing, precision medicine, and early disease detection is accelerating globally. The company is entering a multi-year upgrade cycle with next-generation sequencing platforms that offer faster speeds and lower costs, positioning Illumina to regain market share and strengthen its competitive moat after years of volatility.

Illumina’s technologies are central to explosive growth areas such as liquid biopsy, cancer screening, rare disease diagnosis, and pharmaceutical research, all of which are seeing rising investment and regulatory momentum. With a renewed focus on profitability, a simplified business structure post-divestiture, and expanding partnerships across biotech and healthcare systems, Illumina is set up for margin recovery and revenue reacceleration. As genomics becomes a core pillar of modern medicine, ILMN offers a high-conviction opportunity to participate in the long-term expansion of precision healthcare and the genomic revolution.

Revenue:

1 Year Chart:

Click here to see the chart

Percent From High:

The stock is down 22% from it’s recent highs.

Market Cap: $55.25B

Company Info:

Datadog Inc. (NASDAQ: DDOG) is a leading cloud-observability platform that provides real-time monitoring, analytics, security, and infrastructure visibility for modern applications. Its unified platform integrates logs, metrics, traces, and AI-driven insights across cloud, hybrid, and on-prem environments—making Datadog a mission-critical tool for enterprises operating at scale. Datadog’s mission is to deliver seamless, end-to-end observability that helps companies improve performance, enhance security, and optimize cloud costs as global digital transformation accelerates.

Why We Like It As a Dip Buy:

DDOG looks like a dip buy right now because the recent pullback has been driven far more by market rotation and macro fear than by anything fundamentally wrong with the business. Demand for cloud observability, application monitoring, and security integration continues to strengthen as enterprises scale their digital infrastructure, and Datadog remains one of the only platforms that offers a unified, end-to-end solution across logs, metrics, traces, and AI-driven insights — a competitive advantage that rivals still struggle to match.

The stock sold off due to short-term concerns around cloud optimization, spending moderation, and a broader tech pullback, but none of these issues change the long-term observability cycle or Datadog’s leadership position. Meanwhile, the company continues expanding large enterprise contracts, launching new AI-powered products, and deepening integrations with AWS, Azure, and Google Cloud — all of which support multi-year revenue growth once macro headwinds ease. When you combine a temporary valuation reset with accelerating digital transformation and AI infrastructure growth, DDOG becomes a classic oversold setup with strong asymmetrical upside once sentiment stabilizes.

Revenue:

If you haven’t already, check out our Elite watchlist updated every week:

This is also available in the elite discord.

As always you are more then welcome to send me an email at [email protected] or DM me on instagram @crowntradingllc if you have any questions about the market or stock opportunities.

Thank you for reading!

Jordan

Disclaimer: The stocks mentioned in this email do not represent the exact positions of Crown Trading, but rather ideas and opportunities we are currently monitoring. Just because a stock is featured here does not mean we own or are actively trading it. The buy levels are not recommendations. This is not financial advice, and neither myself nor Crown Trading is recommending that you buy or sell any securities. All information is for educational purposes only and should not be relied upon for investment decisions. Please do your own research before making any trades.